Linagliptina Alter

Linagliptin, the active ingredient in Linagliptina Alter, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Linagliptina Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used to treat disorders of glucose metabolism, primarily type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Monotherapy in type 2 diabetes: reduces HbA1c when diet and exercise are insufficient. - Combination therapy with metformin or other oral antidiabetics: enhances overall glycaemic control. - Use in patients with renal impairment: provides effective glucose lowering without dose adjustment.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection. - Headache: transient mild to moderate pain. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: nausea or abdominal discomfort. - Upper respiratory infection: cough or sore throat. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous pemphigoid: skin blistering disorder. - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Linagliptin should be used with attention to patient‑specific factors and monitoring. - Renal function monitoring: assess kidney status before initiation and periodically. - Hepatic function monitoring: evaluate liver enzymes in patients with liver disease. - Cardiovascular disease: use caution in patients with a history of heart failure. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Concomitant antidiabetic agents: adjust doses to reduce hypoglycaemia risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin may interact with other medicines, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Combined use with insulin or sulfonylureas: increased risk of hypoglycaemia. - Co‑administration with other DPP‑4 inhibitors: additive effect, not recommended. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: monitor blood pressure and renal function. - Diuretics: watch for electrolyte disturbances. - Warfarin: assess INR more frequently. - Digoxin: observe for potential increased serum levels. - Rifampin: may reduce linagliptin plasma concentration.